Ascendis Pharma A (ASND) Total Liabilities (2012 - 2026)
Ascendis Pharma A (ASND) posted Total Liabilities of $1.8 billion for Q1 2026, up 4.0% sequentially from $1.7 billion in Q4 2025, and up 34.79% YoY from $1.3 billion in Q1 2025.
Ascendis Pharma A (ASND) Total Liabilities (2012 - 2026) Analysis & Trends
Ascendis Pharma A has reported Total Liabilities for 15 years, with the latest figure at $1.8 billion in Q1 2026.
- Quarterly Total Liabilities rose 34.79% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 34.79% YoY) and the FY2025 annual result came in at $1.7 billion, up 24.2% from the prior year.
- Total Liabilities advanced to $1.8 billion in Q1 2026 per ASND's latest filing, from $1.7 billion in the prior quarter.
- Over five years, Total Liabilities peaked at $1.8 billion in Q1 2026 and troughed at $767.2 million in Q2 2022.
- A 5-year average of $1.2 billion and a median of $1.1 billion in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities soared 303.36% in 2022, then gained 7.73% in 2023.
- Over 5 years, Total Liabilities stood at $843.1 million in 2022, then gained by 23.95% to $1.0 billion in 2023, then jumped by 31.42% to $1.4 billion in 2024, then climbed by 24.2% to $1.7 billion in 2025, then grew by 4.0% to $1.8 billion in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $1.8 billion, $1.7 billion, and $1.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 1.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.77 Bn |
| Dec 31, 2025 | 1.71 Bn |
| Sep 30, 2025 | 1.55 Bn |
| Jun 30, 2025 | 1.44 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.37 Bn |
| Sep 30, 2024 | 1.31 Bn |
| Jun 30, 2024 | 1.16 Bn |
| Mar 31, 2024 | 1.13 Bn |
| Dec 31, 2023 | 1.05 Bn |
| Sep 30, 2023 | 1.03 Bn |
| Jun 30, 2023 | 826.47 Mn |
| Mar 31, 2023 | 857.68 Mn |
| Dec 31, 2022 | 843.12 Mn |
| Sep 30, 2022 | 828.67 Mn |
| Jun 30, 2022 | 767.20 Mn |
| Mar 31, 2022 | 790.61 Mn |
| Dec 31, 2021 | 230.27 Mn |
| Sep 30, 2021 | 249.62 Mn |
| Jun 30, 2021 | 197.94 Mn |